Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study

About 40 percent of patients who received a combination of Bristol-Myers Squibb Co.’s immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer were alive after two years, according to data presented at the European Society for Medical Oncology 2019 meeting.

Read More »

Genentech’s Tecentriq Improves OS as First-line Monotherapy in Certain People With Advanced NSCLC

Genentech announced positive data from the Phase III IMpower110 study evaluating Tecentriq as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT).

Read More »

AstraZeneca Imfinzi combination fails advanced lung cancer study

A combination of AstraZeneca’s lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations

Read More »

Personal Genome Diagnostics Collaborates with Merck on Global Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy

Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).

Read More »

Survival data boosts Keytruda lead in lung cancer

Merck & Co.’s immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly diagnosed patients with advanced non-small cell lung cancer in a highly anticipated study.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom